LifeMine Therapeutics, Inc. — Form D/A
LifeMine Therapeutics, Inc. of Cambridge, MA, a company, filed a Form D amendment with the SEC on 2019-03-29. The offering totals $70.1M, of which $70.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2019-03-29
- Form: D/A
- Accession: 0001567619-19-007866
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $70.1M
- Amount sold: $70.1M
- Investors: 10
- Date of first sale: 2017-09-15
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-295461
Issuer
- Name: LifeMine Therapeutics, Inc.
- CIK: 0001686955
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 100 Acorn Park, 6th Floor, Cambridge, MA, 02140
- Phone: 617-945-9510
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Yanling L Cao | Director | Cambridge, MA |
| Richard L Klausner | Director | Cambridge, MA |
| Wei L Li | Director | Cambridge, MA |
| Gregory L Verdine | Director | Cambridge, MA |
| Krishna L Yeshwant | Director | Cambridge, MA |
| Gregory L Verdine | Executive Officer | Cambridge, MA |
| WeiQing L Zhou | Executive Officer | Boston, MA |
| Jim L Tananbaum | Director | Cambridge, MA |
| Edward L Hu | Director | Cambridge, MA |
| Hingge L Hsu | Director | Cambridge, MA |
| Hingge L Hsu | Executive Officer | Cambridge, MA |
| WeiQing L Zhou | Director | Boston, MA |
Other filings by this issuer (2)
More